Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
MaxCyte reports strong fourth quarter as full-year revenues fall
(Sharecast News) - Cell engineering technology specialist MaxCyte reported total fourth quarter revenue of $15.7m on Wednesday, up 26% on the same period in 2022. The AIM-traded company said strategic platform licence (SPL) programme-related revenue surged 359% to $8.5m in the quarter, although core business revenue declined 32% to $7.2m.
For the entire 2023 financial year, MaxCyte reported total revenue of $41.3m, reflecting a moderate decrease of 7% compared to 2022.
Core business revenue amounted to $29.8m, down 25%, while SPL programme-related revenue jumped 148% to $11.5m.
MaxCyte ended the year with 23 active SPL agreements, paving the way for over 160 potential programmes.
Among those, 16 were active programmes in clinical stages, while one was already in the commercial phase.
Notably, the company signed three additional SPLs in 2024, bringing the total to 26 active agreements.
As of 31 December, MaxCyte maintained a robust financial position with total cash, cash equivalents, and investments amounting to $211.2m.
"In 2023, we navigated a challenging operating environment in our industry, that included increased capital conservatism and pipeline portfolio reevaluation among our customers," said president and chief executive officer Maher Masoud.
"Our team adapted well to the changing environment last year, and I am confident in our ability to execute across the business this year.
"We are pleased with our accomplishments and progress in 2023, which included supporting the recent FDA approval of CASGEVY by our client, Vertex Pharmaceuticals."
Masoud noted that MaxCyte signed five new SPLs in 2023, and hd seen continued momentum with three additional SPLs signed in January.
"Our pipeline of potential clients remains robust, and we look forward to further expanding our portfolio of SPLs in 2024.
"The opportunity in front of us in the cell therapy industry continues to strengthen, and we will focus on executing in 2024 on our goal of being the industry's premier non-viral cell therapy platform."
At 1031 GMT, shares in MaxCyte were up 0.16% at 315.5p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
